secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0001701541-24-000009
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics reports Q4 2023 net loss of $19.4M, ends year with $131.4M cash
--------------------------------------------------------------------------------

- Net loss Q4 2023 $19.4M vs $21.1M in Q4 2022; full year net loss $82.4M vs $91.2M.
- Cash, cash equivalents, investments $131.4M at Dec 31, 2023; expected to fund operations into Q2 2025.
- Dosed first patient in Phase 2 trial of BDTX-1535 in 1L non-classical EGFRm NSCLC; Phase 2 data expected Q3 2024.
- GBM results for BDTX-1535 in Q2 2024, initial results for BDTX-4933 in KRASm NSCLC in Q4 2024.
- R&D expenses decreased to $59.4M for FY2023 from $64.4M in FY2022, primarily due to reduced early discovery spend.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154124000009/0001701541-24-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154124000009/bdtx-20240312.htm
  HTML page:      https://secwatch.observer/filing/0001701541-24-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer